Differential Regulation of PI Hydrolysis and Adenylyl Cyclase by Muscarinic Receptor Subtypes
Affiliations
Muscarinic acetylcholine receptors (mAChRs), like many other neurotransmitter and hormone receptors, transduce agonist signals by activating G proteins to regulate ion channel activity and the generation of second messengers via the phosphoinositide (PI) and adenylyl cyclase systems. Human mAChRs are a family of at least four gene products which have distinct primary structures, ligand-binding properties and patterns of tissue-specific expression. To examine the question of whether functional differences exist between multiple receptor subtypes, we have investigated the ability of each subtype to regulate PI hydrolysis and adenylyl cyclase when expressed individually in a cell lacking endogenous mAChRs. We show that the HM2 and HM3 mAChRs efficiently inhibit adenylyl cyclase activity but poorly activate PI hydrolysis. In contrast, the HM1 and HM4 mAChRs strongly activate PI hydrolysis, but do not inhibit adenylyl cyclase, and in fact can substantially elevate cAMP levels. Interestingly, the subtypes that we find to be functionally similar are also more similar in sequence. Our results indicate that the different receptor subtypes are functionally specialized.
Higher-order transient structures and the principle of dynamic connectivity in membrane signaling.
Zhang Y, MacKinnon R Proc Natl Acad Sci U S A. 2024; 122(1):e2421280121.
PMID: 39739805 PMC: 11725812. DOI: 10.1073/pnas.2421280121.
Drabek M, Emmerich R, Djulic N, Bunemann M, Schlitzer M, Kolb P ChemMedChem. 2024; 20(3):e202400633.
PMID: 39462201 PMC: 11793849. DOI: 10.1002/cmdc.202400633.
A Brief Overview of Cholinergic and Phosphodiesterase-5 Inhibitors in Diabetic Bladder Dysfunction.
Kallinikas G, Haronis G, Kallinika E, Kozyrakis D, Rodinos E, Filios A Int J Mol Sci. 2024; 25(19).
PMID: 39409033 PMC: 11476953. DOI: 10.3390/ijms251910704.
The M3 Muscarinic Acetylcholine Receptor Can Signal through Multiple G Protein Families.
Smith J, Hilibrand A, Skiba M, Dates A, Calvillo-Miranda V, Kruse A Mol Pharmacol. 2024; 105(6):386-394.
PMID: 38641412 PMC: 11114115. DOI: 10.1124/molpharm.123.000818.
Vaidya S, Guerin A, Walker L, Lawrence A CNS Drugs. 2022; 36(11):1171-1206.
PMID: 36269510 PMC: 9653329. DOI: 10.1007/s40263-022-00964-8.